Requip (Ropinirole) Does NOT Cause Myoclonus
Based on FDA drug labeling and clinical trial data, ropinirole (Requip) is not associated with myoclonus as an adverse effect. The FDA-approved prescribing information for Requip does not list myoclonus among its adverse reactions in either Parkinson's disease or restless legs syndrome (RLS) trials 1.
Key Evidence from Drug Labeling
The comprehensive adverse reaction profile from double-blind, placebo-controlled trials shows:
In Parkinson's Disease patients (with L-dopa):
- Most common adverse reactions (≥2% and greater than placebo): dyskinesia, falls, headache, nausea, somnolence, dizziness, hallucinations, and confusion
- Myoclonus is notably absent from all adverse reaction tables 1
In Restless Legs Syndrome patients:
- Most common adverse reactions: nausea (40%), somnolence (12%), dizziness (11%), vomiting (11%)
- Again, no mention of myoclonus in any frequency category 1
Postmarketing surveillance identified withdrawal symptoms as the primary additional concern, but myoclonus was not reported 1.
Important Clinical Context
Clarification on Drug Name
The question appears to confuse ropinirole (Requip) with rasagiline (Azilect). These are distinct medications:
- Ropinirole (Requip): Dopamine agonist
- Rasagiline (Azilect): MAO-B inhibitor
Even for rasagiline, a recent post-marketing surveillance study in 961 Japanese patients with Parkinson's disease found no myoclonus among adverse drug reactions over 24 months of observation 2.
When Myoclonus Occurs in Parkinson's Disease
Myoclonus in Parkinson's patients is more commonly associated with:
Post-hypoxic injury (e.g., after cardiac arrest) - where myoclonus occurs in 18-25% of comatose patients and represents brain injury rather than drug effect 3
Other medications with established myoclonus risk 4, 5, 6:
- Opioids (fentanyl, morphine, meperidine)
- Antidepressants (SSRIs, tricyclics)
- Antibiotics (cephalosporins, fluoroquinolones)
- Antiseizure medications (gabapentin, pregabalin, valproate)
- Anesthetics (etomidate, propofol)
Disease progression itself, particularly in advanced Parkinson's disease
Clinical Pitfall to Avoid
Do not attribute myoclonus to ropinirole without investigating other causes. If a patient on Requip develops myoclonus, systematically evaluate:
- Concomitant medications (especially those listed above)
- Metabolic derangements (renal failure, hepatic encephalopathy)
- Structural brain lesions
- Hypoxic-ischemic injury
- Underlying neurodegenerative progression
The evidence consistently shows that ropinirole's adverse effect profile centers on dopaminergic effects (dyskinesia, hallucinations, orthostatic hypotension, nausea) rather than myoclonic movements 1.